Alistair Cook

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +7

Identification of a Bipotent Epithelial Progenitor Population in the Adult Thymus

Svetlana Ulyanchenko, Kathy E. O’Neill, Tanya L. Medley et al. · Cell Reports · 2016 · 119 citations · Full text

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Anna K. Nowak, Alistair Cook, Alison M. McDonnell et al. · Annals of Oncology · 2015 · 98 citations · Full text

Phase 1B, Malignant Pleural Mesothelioma, Medicine +6

Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies

Alistair Cook, Alison M. McDonnell, Richard Lake et al. · OncoImmunology · 2015 · 75 citations · Full text

Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment

Wayne J. Aston, Danika E. Hope, Alistair Cook et al. · OncoImmunology · 2019 · 36 citations · Full text

Cancer Immunosurveillance, Allergy, Peripheral Blood Lymphocytes +14